Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-23 (Cancelled).

24 (Original) A method of preparing a pharmaceutical composition for the treatment of an ear disorder in the form selected from a foam and mousse, the method comprising the steps of:

a. providing a pharmaceutical agent known to affect an ear disorder;

b. admixing the pharmaceutical agent of step (a) with a suitable pharmaceutically acceptable carrier comprising a dispersing agent that is a foam forming agent;

c. introducing the mixture of (b) into a dispensing device adapted for the dispensing the composition to the external auditory meatus in the form of a foam or mousse.

Claims 25-28 (Cancelled).

29. (Original) The method according to claim 24 wherein said dispensing device is a metered dose dispensing device.

Claims 30-39 (Cancelled).

40. (Original) A method for the treatment of an ear disorder in a subject in need of such treatment, the method comprising the steps of:

a. providing a pharmaceutical agent known to affect an ear disorder;

b. admixing the pharmaceutical agent of step (a) together with a pharmaceutically acceptable carrier comprising a dispersing agent that is a foam forming agent;

c. introducing the mixture formulation of step (b) in a container that enables the dispersion of said mixture in a form selected from foam and mousse; and

d. administering the formulation of step (c) to the external auditory meatus of said subject so as to thereby treat the ear disorder.

Claims 41-42 (Cancelled).

43. (Original) The method according to claim 40 wherein the dispensing device is selected from an aerosol dispensing device and a non-aerosol dispensing device.

Claim 44 (Cancelled).

45. (Original) The method according to claim 40 wherein said dispensing device is a metered dose dispensing device.

Claims 46-53 (Cancelled).

54. (Original) The method according to claim 40 wherein the least one pharmaceutically active agent is selected from an antibiotic agent, an antibacterial agent, an antifungal agent, a steroid agent, an anti-inflammatory agent, a local anesthetic agent and a mixture thereof, in a therapeutic effective amount.

Claims 55-63 (Cancelled).

64. (New) A dispensing device for the administration of a pharmaceutical composition to the ear of a subject in the form of a foam or mousse, the device comprising:

a. a pharmaceutical composition comprising at least one pharmaceutical agent known to affect an ear disorder, and a pharmaceutically acceptable carrier comprising at least one dispersing agent that is a foam forming agent;

b. a container comprising the pharmaceutical composition, and

c. an extension extending from the container, wherein the extension is adapted to access the outer ear of the subject,

wherein the dispensing device is adapted for the dispensing the pharmaceutical composition of a) to the external auditory meatus in a form selected from a foam and a mousse.

65. (New) The dispensing device according to claim 64 wherein the dispersing agent is selected from a surfactant, a cholesteryl ester, a fatty acid, a phospholipid, a carbohydrate and a protein.

66. (New) The dispensing device according to claim 65 wherein the surfactant is selected from a natural ionic surfactant, a synthetic ionic surfactant, a natural non-ionic surfactant, a synthetic non- ionic surfactant and a mixture thereof.

67. (New) The dispensing device according to claim 64 wherein the dispensing device is selected from an aerosol and a non-aerosol dispensing device.

68. (New) The aerosol dispensing device according to claim 67, further comprising an aerosol propellant.

69. (New) The dispensing device according to claim 64 wherein the dispensing device is a metered dose dispensing device.

70. (New) The dispensing device according to claim 64 wherein the pharmaceutical composition comprises an oil-in-water emulsion or microemulsion, or a water-in-oil emulsion.

71. (New) The dispensing device according to claim 64 wherein the pharmaceutical composition is dispensed as an aqueous based foam.

72. (New) The dispensing device according to claim 64 wherein the pharmaceutical composition is dispensed as a lipid based mousse.

73. (New) The dispensing device according to claim 64, further comprising an actuator mounted on the extension, wherein the pharmaceutical composition is ejected through the actuator.

74. (New) The dispensing device according to claim 73 wherein the actuator is adapted to prevent entry of the extension into and injury of the ear canal.

75. (New) The dispensing device according to claim 64 wherein the at least one pharmaceutically active agent is selected from an antibiotic agent, an antibacterial agent, an antifungal agent, a steroid agent, an anti-inflammatory agent, a local anesthetic agent and a mixture thereof, in a therapeutically effective amount.

76. (New) The dispensing device according to claim 75 wherein the antibiotic agent is selected from the group consisting of amikacin, gentamycin, tobramycin, streptomycin, netilmycin, kanamycin ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, enoxacin, sulfonamides, polymyxin, chloramphenicol, neomycin, paramomomycin, colistimethate, bacitracin, vancomycin, tetracyclines, rifampins, cycloserine, beta-lactams, cephalosporins, and pharmaceutically acceptable derivatives thereof.

77. (New) The dispensing device according to claim 75 wherein the antibacterial agent is selected from zinc, acetic acid or boric acid or a mixture thereof.

78. (New) The dispensing device according to claim 75 wherein the steroid agent is selected from the group consisting of betamethasone, betamethasone dipropionate, fluocinonide, fluocinoline acetonide, hydrocortisone, methylprednisolone, clobetasol, beclomethasone, dexamethasone sodium phosphate, triamcinolone and pharmaceutically acceptable derivatives thereof.

79. (New) The dispensing device according to claim 75 wherein the antifungal agent is selected from the group consisting of amphotericins, fluconazole, flucytosine,

natamycin, miconazole, ketoconazole, amphotericin B, nystatin, cromolyn, lodoxamide, levocabastin, naphazolin, antazoline, pheniramimane and pharmaceutically acceptable derivatives thereof.

80. (New) The dispensing device according to claim 75 wherein the anti-inflammatory agent is selected from the group consisting of non-steroidal anti-inflammatory agents (NSAID), antipyrin and pharmaceutically acceptable derivatives thereof.

81. (New) The dispensing device according to claim 75 wherein the local anesthetic agent is selected from the group consisting of benzocaine, benzyl benzoate, bupivacaine, calamine, chloroprocaine, chloroxylenol, cinchocaine, cocaine, dexivacaine, diamocaine, dibucaine, dyclonine, etidocaine, hexylcaine, ketamine, levobupivacaine, lidocaine, menthol, mepivacaine, oxethazaine, phenol, pramoxine, prilocaine, amethocaine, tetracaine, proparacaine, propoxycaine, pyrrocaine, resorcinol, risocaine, rodocaine, ropivacaine, tetracaine, and pharmaceutically acceptable derivatives thereof.